Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows

Benzinga_recent_news12-03

Pharvaris N.V. (NASDAQ:PHVS) on Wednesday shared topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks. HAE is a rare genetic...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2588404708?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/03/Medical-Concept-Meaning-Angioedema-With-.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-03 23:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2588404708","market":"us","top_or_hot":-1,"title":"Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows","media":"Benzinga_recent_news","content":"<div>\n<p>Pharvaris N.V. (NASDAQ:PHVS) on Wednesday shared topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks.\nHAE is a rare genetic...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49185642/pharvaris-pill-provides-rapid-relief-in-patients-with-rare-swelling-attacks-data-shows\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPharvaris Pill Provides Rapid Relief In Patients With Rare Swelling Attacks, Data Shows\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-03 23:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/12/49185642/pharvaris-pill-provides-rapid-relief-in-patients-with-rare-swelling-attacks-data-shows><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pharvaris N.V. (NASDAQ:PHVS) on Wednesday shared topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks.\nHAE is a rare genetic...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49185642/pharvaris-pill-provides-rapid-relief-in-patients-with-rare-swelling-attacks-data-shows\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/12/49185642/pharvaris-pill-provides-rapid-relief-in-patients-with-rare-swelling-attacks-data-shows","article_id":"2588404708","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/03/Medical-Concept-Meaning-Angioedema-With-.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49185642/pharvaris-pill-provides-rapid-relief-in-patients-with-rare-swelling-attacks-data-shows","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2588404708","pubTimestamp":1764774540,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Pharvaris reports Phase 3 data showing its oral HAE treatment delivers rapid relief, fewer second doses and strong safety results.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IONS":"Ionis Pharmaceuticals, Inc","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","LU0124384867.USD":"贝莱德新能源基金A2","HAE":"美国血液技术","BK4161":"工业机械","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1978683503.SGD":"Blackrock Sustainable Energy A2 SGD-H","BK4585":"ETF&股票定投概念","BK4198":"医疗保健用品","PHVS":"Pharvaris N.V.","BK4139":"生物科技","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","IR":"英格索兰","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","KALV":"Kalvista Pharmaceuticals Inc","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4588":"碎股","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC"},"translate_title":"数据显示，Pharvaris药丸可快速缓解罕见肿胀发作的患者","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IR":1,"KALV":1,"HAE":1,"IONS":1,"PHVS":1},"content_text":"Pharvaris N.V. (NASDAQ:PHVS) on Wednesday shared topline data from the RAPIDe-3 Phase 3 trial of deucrictibant for the on-demand treatment of hereditary angioedema (HAE) attacks.\nHAE is a rare genetic disorder that causes recurrent, severe swelling in the skin, face, limbs, and internal organs, including the airway and gastrointestinal tract.\nThe study enrolled a total of 134 participants that evaluated the orally administered deucrictibant immediate-release (IR) capsule for the on-demand treatment of attacks in people 12 years and older with HAE.\nAlso Read: BioCryst Just Ditched Its Europe Business — Here’s Why Investors Are Cheering\nThe company said the data from its first pivotal Phase 3 study will serve as the basis for marketing authorization applications, which are planned to be filed starting in the first half of 2026.\nCompared to placebo, deucrictibant demonstrated faster median time to onset of treatment response:\nShorter median time to substantial symptom relief and earlier complete symptom resolution.\nThe data also showed fewer attacks treated with a second dose or rescue medication within 12 hours.\nIn RAPIDe-3, deucrictibant was well tolerated with no treatment-related serious adverse events and no participants discontinuing treatment due to treatment-emergent adverse events.\nAn open-label extension of deucrictibant for the on-demand treatment of HAE attacks, RAPIDe-2 Part B, is ongoing.\nIn August, the U.S. Food and Drug Administration (FDA) approved Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older.\nThe study met its primary endpoint, with Dawnzera Q4W significantly reducing the monthly HAE attack rate by 81% compared to placebo over 24 weeks.\nMean attack rate reduction increased to 87% when measured from the second dose, a key secondary endpoint.\nIn July, the FDA approved KalVista Pharmaceuticals Inc.'s (NASDAQ:KALV) Ekterly (sebetralstat) for acute attacks of HAE in adult and pediatric patients aged 12 years and older.\nEkterly is the first and only oral on-demand treatment for HAE.\nPHVS Price Action: Pharvaris shares were up 12.32% at $27.09 at the time of publication on Wednesday, according to Benzinga Pro data.\nRead Next:\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2588404708","isCrawlerRequest":true}